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We synthesized 16 pyrrolidine-based oxy-peptide nucleic acid (POPNA) monomers carrying 
four different nucleobases onto four different stereoisomers of pyrrolidine rings. Using these 
monomers, we prepared POPNA oligomers, which formed sequence-specific hybrids with 
DNAs. The oligomer configurations influenced the hybrid stability. The oligomers were not 
taken into CHO cells. However, they could enter the cell cytoplasm when mixed with the 
influenza virus hemagglutinin peptide-arginine heptamer conjugate. 
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1. Introduction 
Nielsen-type peptide nucleic acids (PNAs; Figure 1 A) are 
DNA surrogates that form stable duplexes and triplexes with 
DNAs (Figure 1 B) and RNAs.1 The non-ionic backbone of 
PNAs leads to stable hybrids with the nucleic acids, but at the 
same time, the neutral backbone results in low water solubility of 
the PNAs owing to the formation of aggregates in aqueous 
solutions. This undesirable property limits the use of PNAs in 
medicinal and other applications. One way of overcoming this 
drawback is to conjugate PNAs with cationic peptides such as 
cell-penetrating peptides (CPPs).2 However, the PNA-CPP 
conjugates cause non-specific interactions with nucleic acids 
consisting of anionic backbones. 
To overcome these drawbacks, we synthesized new peptide 
nucleic acids by introducing ether linkages in the main chain of 
peptide nucleic acids; An example is oxy-PNA (OPNA; Figure 1 
C).3 Introduction of ether linkages in the PNA backbones can 
improve the water solubility of the PNAs.3a, 4 OPNAs are also not 
expected to non-specifically interact with nucleic acids because 
of the non-ionic backbone of the OPNAs. The OPNA oligomers 
can be successfully hybridized with the complementary DNAs, 
which is indicated by very sharp melting curves. However, 
because OPNAs do not form stable hybrids with RNAs, we 
designed and synthesized other types of oxy-PNAs that whose 
structures resembled the structure of DNA by introducing 
pyrrolidine rings in the backbone; An example is pyrrolidine-
based oxy-PNAs (POPNAs; Figure 1 D).5,6 
 
Figure 1. Chemical structures of PNA, DNA, OPNA, and 
POPNA oligomers. 
The pyrrolidine ring possesses two chiral centers and there 
are four stereoisomers (cis-L-, trans-L-, cis-D-, and trans-D-
configurations). We have previously shown that among the 
adenine homo-oligomers of the four different configurations, 
trans-L-POPNA and cis-L-POPNA form the most stable hybrids 
with the complementary RNA and DNA, respectively.5d In this 
study, we synthesized sixteen POPNA monomers of four 
stereoisomers on the pyrrolidine ring with four different 
nucleobases (adenine (A), thymine (T), guanine (G), and cytosine 
(C)). The coupling of these monomers resulted in the synthesis of 
POPNA oligomers that contained sequences of the four 
nucleobases. The coupling was performed by Fmoc-based solid-
phase peptide synthesis (SPPS). The formation of hybrids of 
these POPNA oligomers with the DNA sequences was examined 
by studying the melting curves. We also investigated the cellular 
uptake and endosomal release of the POPNA oligomers. The 
cellular uptake of POPNA oligomers was achieved by mixing the 
POPNA oligomers with HA2 (an N-terminal 23-mer peptide of 
the influenza virus hemagglutinin protein)7 conjugated with a 
CPP consisting of an arginine heptamer.8 
2. Results and discussion 
2.1. Synthesis of POPNA monomers and their oligomers 
Sixteen POPNA monomers were synthesized from two 
compounds, 1 (the trans-L-1, see Scheme 1) and the cis-D-1. 
These starting materials, 1 and the cis-D-1, were synthesized 
from trans-L-hydroxyproline and cis-D-hydroxyproline in 6 steps 
according to the literature procedure, respectively.5b Cis-L-2 and 
trans-D-2 were synthesized in two steps through the inversion of 
the free hydroxyl group—in the 4th position of the pyrrolidine 
ring of trans-L-1 and cis-D-1—by formylation and subsequent 
treatment with aqueous ammonia in methanol. The synthetic 
routes from the compound 2 to the trans-L-POPNA monomers 
with A, T, G, and C nucleobases are shown in Scheme 1.  
For preparing the trans-L-POPNA T monomer, first, 
compound 3 was synthesized by a direct substitution of the 
hydroxyl group of 2 with N3-benzoylthymine9 under Mitsunobu 
conditions.5,10 Next, 3 was treated with 30% HBr/AcOH to 
remove the tert-butyloxycarbonyl (Boc), tert-butyl ester (tBu), 
and benzoyl (Bz) protecting groups. The resulting free amine was 
then protected with 9-fluorenylmethyl succinimidyl carbonate 
(Fmoc-OSu) to give the trans-L-POPNA T monomer 4 in an 
overall yield of 85% from 2. For the trans-L-POPNA A monomer, 
the hydroxyl group of 2 was first reacted with methanesulfonyl 
chloride (Ms-Cl) to give the mesylate 5 in 90% yield. Next, 5 
was alkylated with N6-benzoyladenine to give compound 6 in 
55% yield.11 Removal of Boc, tBu, and Bz protecting groups on 6 
with 30% HBr/AcOH and treatment with Fmoc-OSu gave the 
trans-L-POPNA A monomer 7 in an overall yield of 48% from 2. 
In the case of the trans-L-POPNA C monomer, first, N4-
benzyloxycarbonylcytosine (N4-Cbz-cytosine)12 was introduced 
to 5 to give compound 8 in 40% yield. Next, Boc and tBu 
protecting groups of 8 were removed with TFA to avoid 
deprotection of the Cbz group. The resulting free compound was 
treated with Fmoc-OSu to give the trans-L-POPNA C monomer 
9 in an overall yield of 29% from 2. In the case of the trans-L-
POPNA G monomer, first, alkylation of 2-amino-6-chloropurine 
with 5 gavecompound 10 in 42% yield. Conversion of the 6-
chloro group on 10 with 2-nitrophenoxy gave compound 11 in 
86% yield. Next, the N2-amino group on 11 was protected with 
an isobutyryl group to avoid undesirable acylation in the peptide-
coupling step, to give compound 12 in 93% yield. Subsequently, 
removal of the 2-nitrophenoxy group on 12 with 1,1,3,3-
tetramethylguanidine gave compound 13 in 65% yield.13 Finally, 
removal of Boc and tBu protecting groups with 30% HBr/AcOH 
and treatment with Fmoc-OSu gave the trans-L-POPNA G 
monomer 14 in an overall yield of 22% from 2. 
All the final products (4, 7, 9, and 14) were characterized by 
1H-NMR, 13C-NMR, HRMS, and RP-HPLC (See supplementary 
data). Other POPNA monomers of different configurations (cis-
L-POPNA, trans-D-POPNA, and cis-D-POPNA monomers with 
A, T, G, and C nucleobases) were also synthesized from 
corresponding starting materials and characterized in a similar 
manner. 
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Scheme 1. Synthetic routes of the trans-L-POPNA monomers 4, 
7, 9, and 14: (i) HCOOH, DEAD, Ph3P, THF/Toluene, rt, 
overnight; (ii) 25% NH3 aq, MeOH, rt, 1 h; (iii) N3-
Benzoylthymine, DEAD, Ph3P, THF/Toluene, rt, overnight; (iv) 
30% HBr/AcOH, rt, 30 min; (v) Fmoc-OSu, NaHCO3, 
H2O/MeCN (1/1, v/v), rt, overnight; (vi) Ms-Cl, TEA, DCM, rt, 3 
h; (vii) N6-Benzoyladenine, K2CO3, 18-Crown-6, DMF, 65 ˚C, 
overnight; (viii) N4-Cbz-cytosine, K2CO3, 18-Crown-6, DMF, 65 
˚C, overnight; (ix) TFA, rt, 30 min; (x) 2-NH2-6-Cl-Purine, 
K2CO3, 18-Crown-6, DMF, 65 ˚C, overnight; (xi) 2-Nitrophenol, 
DABCO, TEA, 1,2-dichloroethane, rt, overnight; (xii) iPrCOCl, 
pyridine, rt, overnight; (xiii) 2-Nitrobenzaldoxime, 1,1,3,3-
tetramethylguanidine, MeCN, rt, overnight. 
Trans-L-POPNA oligomers containing four types of 
nucleobases were synthesized by SPPS according to previous 
procedures.5 The sequences of trans-L-POPNA oligomers were 
H-TGGTGCGAA-Lys-NH2(trans-L-POPNA9), Fam-Sp2-
TGGTGCGAATTC-Lys-NH2(Fam-trans-L-POPNA12, where 
Sp2 indicates a linker consisting of ethylene glycol units and Fam 
represents 5(6)-carboxy-fluorescein used as a fluorescent label), 
Fam-Sp2-TGGTGCCTC-Sp2-(Arg)7-NH2(Fam-trans-L-
POPNA9-R7), and Fam-Sp2-CAGTTAGGGTTAG-Gly-
NH2(Fam-trans-L-POPNA13). Lys, Arg, and Gly indicate lysine, 
arginine, and glycine, respectively. The N-terminals and C-
terminals of these oligomers are primary amines and primary 
amides, respectively. The crude oligomers were purified by 
preparative HPLC, and the purified oligomers were identified by 
MALDI-TOF Mass (trans-L-POPNA9, calcd. [M + H]+ = 
2635.13, obsd. [M + H]+ = 2634.26; Fam-trans-L-POPNA12, 
calcd. [M + H]+ = 3918.57, obsd. [M + H]+ = 3917.95; Fam-
trans-L-POPNA9-R7, calcd. [M + H]+ = 4174.91, obsd. [M + H]+ 
= 4175.50; Fam-trans-L-POPNA13, calcd. [M + H]+ = 4163.63, 
obsd. [M + H]+ = 4163.26).14 
2.2. Hybrid formation of POPNA oligomers with DNAs 
Melting curves of trans-L-POPNA9 in equimolar mixtures 
with DNA (5′-TTCGXACCA-3′, X = A, T, G, and C) are shown 
in Figure 2. In the case of the completely complementary DNA 
(X = C), the sigmoidal melting curve was observed having a 
melting temperature (Tm) of 22.2 ˚C. The Tm’s of the hybrids of 
trans-L-POPNA9 with DNA sequences having a single-
mismatched, where X = A, T, and G, were 21.4, 21.0, and 20.3 
˚C, respectively. These results indicate that trans-L-POPNA9, 
having a sequence that contains the four types of nucleobases, 
forms moderate sequence-specific hybrids with DNAs. 
 
Figure 2. Temperature dependences of absorption intensities at 
260 nm for equimolar mixtures of trans-L-POPNA9 (N′-
TGGTGCGAA-C′)/DNA (5′-TTCGXACCA-3′, X = A, T, G, and 
C) in 100 mM NaCl, 10 mM NaH2PO4, and 0.1 mM EDTA, with 
pH 7.0. [trans-L-POPNA9] = [DNA] = 2.5 μM. The melting 
curves were recorded by heating the solution at 0.5 ˚C/0.5 min. 
The observed absorbance has been normalized at 60 ˚C. 
To examine the effect on the configuration of POPNAs when 
hybridized with DNAs, we synthesized13-mer POPNA 
oligomers of different configurations (trans-L POPNA13, cis-L 
POPNA13, trans-D-POPNA13, and cis-D-POPNA13; with a 
sequence of H-CAGTTAGGGTTAG-NH2.) and we estimated the 
melting temperatures of the oligomers-DNAs hybrids from their 
respective melting curves. Melting temperatures of these hybrids 
are listed in Table 1. Of these oligomers, trans-D-POPNA13 
formed the most stable hybrid with the fully complementary 
DNA (Tm = 41.2 ˚C). Trans-L-POPNA13, cis-L-POPNA13 and 
cis-D-POPNA13 showed lower hybrid stabilities with the fully 
complementary DNA than trans-D-POPNA13. All POPNA 
oligomers formed moderate sequence-specific hybrids with 
DNAs. Successful hybridizations of all the stereoisomers of 
POPNA are explained in terms of their flexible main chains that 
contain ether linkages. However, the higher stability of the 
hybrid between trans-D-POPNA and DNA, than those of the 
other oligomers/DNA hybrids, is a consequence of its restricted 
main chain, which contains pyrrolidine rings. Moreover, hybrids 
of POPNA oligomers with DNAs are preferentially formed with 
antiparallel orientations, especially trans-L-POPNA13 and cis-L-
POPNA13 (32.9 ˚C and 33.6 ˚C for antiparallel orientation and 
DNA (X = C)
DNA (X = A)
DNA (X = T)
DNA (X = G)
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28.6 ˚C and 27.3 ˚C for parallel orientation, respectively). This 
result also suggests that configurations of POPNA have a 
tendency to form a single, stable hybrid with DNA. 
Table 1. Melting temperatures (Tm) of hybrids of 13-mer 
POPNAs (N'-CAGTTAGGGTTAG-C') with DNAs (5'-
CTAACCXTAACTG-3', X = A, T, C, and G). 
aMeasurement conditions of melting curves of these mixtures are 
the same as those of Figure 1. 
bValues in parentheses show a difference of Tm (antiparallel 
orientation) for Tm (parallel orientation). 
2.3. Transport of POPNA oligomers into cytoplasm 
We examined the internalization of the POPNA oligomer into 
Chinese hamster ovary (CHO) cells with confocal laser scanning 
microscopy. First, the CHO cells were cultured in the presence of 
10 μM Fam-trans-L-POPNA12. However, no fluorescence was 
observed with the CHO cells. Unfortunately, the POPNA 
oligomer did not internalize into the cells by themselves. In the 
case of the trans-L-POPNA oligomer conjugated with a CPP 
(Fam-trans-L-POPNA9-R7), the fluorescence from Fam was 
observed inside the cells, as shown in Figure 3. However, this 
image indicates that the fluorescence is mostly confined in small 
vesicular compartments. These endosomes were observed even 
after 6 h of incubation, without a decrease in fluorescence. These 
results suggest that the POPNA oligomer conjugated with a CPP 
internalized inside CHO cells by an endocytosis mechanism and 
that they remained inside the endosomes. 
To release the POPNA oligomer from the endosomes, we 
synthesized an HA2 (Tmr-HA2-R7, a peptide that disrupts 
endosomes)7 labeled with a 5(6)-tetramethylrhodamine 
fluorophore at the N-terminal and conjugated with R7 at the C-
terminal. The CHO cells were incubated with the mixture of 
Fam-trans-L-POPNA13 and Tmr-HA2-R7. The fluorescence 
from the CHO cells, after incubation with Fam-trans-L-
POPNA13, in the absence and presence of Tmr-HA2-R7 was 
measured. Incubation with only Fam-trans-L-POPNA13, showed 
no internalization of the oligomer. On the other hand, Fam-trans-
L-POPNA13 was successfully internalized inside CHO cells in 
the presence of Tmr-HA2-R7 (Figure 4), and more importantly, 
both the red (Tmr) and green (Fam) fluorescence were detected 
throughout the whole cell. This indicates that the POPNA 
oligomers were taken up into the cells with the Tmr-HA2-R7 and 
released into the cytoplasm with the disruption of the endosomes 
by the HA2 peptide within 1 h. 
 
Figure 3. Confocal microscopy images of CHO cells cultured for 
2 h at 37 ˚C in the presence of 1.0 μM Fam-trans-L-POPNA9-R7. 
The left image shows the green fluorescence image from Fam-
fluorescence. The right image is a superimposed image of the 
phase contrast and the fluorescence images. 
 
Figure 4. Confocal microscopy images of CHO cells cultured for 
1 h at 37 ˚C in the presence of Fam-trans-L-POPNA13 and Tmr-
HA2-R7 (Tmr-Sp2-GLFEAIEGFIENGWEGMIDGWYG-Sp2-
RRRRRRR-NH2). [Fam-trans-L-POPNA13] = [Tmr-HA2-R7] = 
10 μM.15 The top left image shows the phase contrast image of 
the optical section at the middle of cells. The top right image 
shows the green fluorescence image from Fam groups. The 
bottom right image shows the red fluorescence image from Tmr 
groups. 
3. Conclusions 
In summary, we synthesized sixteen POPNA monomers with 
four types of nucleobases on four stereoisomers of the 
pyrrolidine rings. POPNA oligomers of a mixed sequence of four 
types of nucleobases were also synthesized. These POPNA 
oligomers were successfully hybridized with DNAs. The 
configurations of POPNA oligomers affect the hybridization. The 
POPNA oligomers were readily taken up inside the cytoplasm of 
CHO cells when mixed with a HA2-CPP conjugate. The 
antisense effect of the four types of stereoisomers of the POPNA 
oligomers, in combination with the HA2-CPPconjugate is now 
under investigation. 
4. Experimental 
4.1. General 
Diethyl azodicarboxylate (DEAD), triphenylphosphine (Ph3P), 
methanesulfonylchloride (Ms-Cl), 25% aqueous ammonia, 
triethylamine (TEA), N6-benzoyladenine, 18-crown-6, 2-amino-
6-chloropurine, 2-nitrophenol, 2-nitrobenzaldoxime, K2CO3, 
 
POPNA 
DNA (5′-CTAACCXTAACTG-3′)a 
Antiparallel orientation  Parallel 
orientation 
X = C (full-
matched) 
A G T  C 
trans-L 32.9 29.8 30.2 29.0  28.6 (4.3)b 
trans-D 41.2 37.8 37.4 35.7  39.9 (1.4) 
cis-L 33.6 30.2 28.6 27.8  27.3 (6.3) 
cis-D 32.5 28.9 27.2 26.3  30.8 (1.6) 
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NaHCO3, KHSO4, MgSO4, pyridine, and other solvents were 
purchased from Wako Chemicals (Tokyo, Japan). Fmoc-Gly-OH, 
Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, 30% hydrogen 
bromide in acetic acid (HBr/AcOH), trifluoroacetic acid (TFA) 
and 9-fluorenylmethyl succinimidyl carbonate (Fmoc-OSu) were 
purchased from Watanabe Chemicals (Hiroshima, Japan). Formic 
acid (HCOOH) and Fmoc-NH-PEG-COOH(Sp2) were purchased 
from Merck (NJ, USA). 1,4-Diazabicyclo[2.2.2]octane 
(DABCO), isobutyrylchloride (iPrCOCl), 1,1,3,3-tetramethyl-
guanidine, 6-[fluorescein-5(6)-carboxamido]hexanoic acid N-
hydroxysuccinimide ester (Fam) and 6-carboxy-tetramethyl-
rhodamine N-succinimidyl ester (Tmr) were purchased from 
Sigma-Aldrich (MO, USA). DNA oligomers were purchased 
from Invitrogen Japan (Tokyo, Japan). These reagents were used 
without purification. Distilled water was used throughout the 
synthesis. 1H-NMR and 13C-NMR spectra were recorded on a 
Varian Mercury 300 spectrometer. High-resolution mass spectra 
were measured on Nihon Denshi MS 700. MALDI-TOF Mass 
spectra were measured on Applied Biosystems Voyager DE-Pro, 
and hybridization behavior was observed on a JASCO V-560 
UV-vis spectrophotometer equipped with a temperature 
controller. Fluorescent images from confocal laser scanning 
microscopy were observed on Olympus FLUOVIEW FV-1000. 
Key intermediates for POPNA monomers, 1 (trans-L 
configuration), cis-L-configurated 1(2), cis-D-configurated 1, and 
trans-D-configurated 1were synthesized according to procedures 
that were previously reported.5b 
4.2. Synthesis of POPNA T monomers 
4.2.1. (2S,4R)-4-(3-Benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-
pyrimidin-1-yl)-2-tert-butoxycarbonylmethoxymethyl-
pyrrolidine-1-carboxylic acid tert-butyl ester (3) 
2 (3.51 g, 10.6 mmol), Ph3P (4.17 g, 15.9 mmol), and N3-
benzoylthymine (2.39 g, 10.6 mmol) were added to 
tetrahydrofuran (THF)(10 mL). To this mixture was added 
DEAD (2.49 mL, 15.9 mmol) under argon atmosphere at –15˚C 
and then stirred at room temperature overnight. The resultant 
mixture was evaporated to dryness and the residue was washed 
several times with 50/50 ethyl acetate (AcOEt)/hexane (Hex) 
mixture and dried in vacuo. The residue was chromatographed on 
silica gel with 40/60 AcOEt/Hex mixture as eluting solvent. The 
title compound 3 was obtained as white powder. Yield: 17%. Rf 
(AcOEt/Hex = 5/5, v/v): 0.41. 1H-NMR (300MHz, CDCl3):δ1.5 
(s+s, 18H, Boc CH3 and tert-butyl CH3), 1.96 (s, 3H, thymine 
CH3), 2.2-2.6 (m, 2H, C3′H2), 3.4-4.3 (m, 7H, C5′H2, Cα-CH2-O-
CH2-CO and C2′H), 5.2 (m, 1H, C4′H), 7.1 (s, 1H, C6H), 7.4-7.9 
(m, 5H, phenyl). 13C-NMR (75 MHz, CDCl3):δ 14.3 (thymine 
CH3), 28.1 and 28.4 (Boc CH3 and tert-butyl CH3), 32.4 (C3′), 
49.6 (C5′), 55.8 (C2′), 62.3 (C4′), 68.9 (O-CH2-CO), 72.4 (Cα-
CH2-O), 80.5 and 81.7 (Boc C and tert-butyl C), 111.5 (C5), 
129.1, 130.4, 131.5, and 134.9 (phenyl), 136.3 (C6), 149.8 (C2), 
154.5 (Boc amide), 161 (C4), 168.9 (tert-butyl ester and benzoyl 
amide). 
4.2.2. (2S,4R)-2-Carboxymethoxymethyl-4-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)-pyrrolidine-1-carboxylic acid 
9H-fluoren-9-ylmethyl ester (4, trans-L-POPNA T monomer)  
3 (1.00 g, 1.83 mmol) was treated with 30% HBr/AcOH (10 mL) 
for 30 min at room temperature. The resultant mixture was 
evaporated to dryness. The residue was dissolved in 5% aqueous 
NaHCO3 (10 mL) to adjust the pH to 8. A solution of Fmoc-OSu 
(0.71 g, 2.20 mmol) in acetonitrile (MeCN, 10 mL) was added to 
the aqueous solution with stirring under ice cooling. The reaction 
mixture was stirred at room temperature overnight and 
evaporated to dryness. The residue was dissolved in water and 
the aqueous layer was washed three times with diethyl ether 
(Et2O, each 30 mL), acidified to pH 7 with 5% aqueous KHSO4, 
and extracted three times with AcOEt. The AcOEt layer was 
washed with water and brine, then, dried over MgSO4. Filtration 
followed by solvent evaporation gave the title compound 4. 4 
was obtained as a white powder. 4 was purified by preparatory 
RP-HPLC (C18 column) before using to SPPS. Yield: 60%. 1H-
NMR (300MHz, CDCl3):δ1.7 and 1.8 (s+s, 3H, thymine CH3), 
2.0-2.4 (m, 2H, C3′H2), 3.0-4.2 (m, 7H, C5′H2, Cα-CH2-O-CH2-
CO, and Fmoc CH), 4.3 (m, 2H, Fmoc CH2), 4.4-4.7 (m, 1H, 
C2′H), 5.0-5.3 (m, 1H, C4′H), 7.3-7.9 (m, 8H, Fmoc aromatic 
ring), 7.6 (s, 1H, C6H). 13C-NMR (75 MHz, CDCl3):δ 12.5 
(thymine CH3), 32.4 and 33.4 (C3′), 47.2 (Fmoc CH), 49.6 (C5′), 
53.0 and 54.0 (C4′), 55.9 and 56.4 (C2′), 66.6 (Fmoc CH2), 68.1 
(O-CH2-CO), 71.8 (Cα-CH2-O), 111.9 (C5), 119.9, 124.9, 127.0, 
127.7, 141.3, and 143.8 (Fmoc aromatic ring), 136.6 (C6), 151.3 
(C2), 154.5 (Fmoc amide), 164.2 (C4), 173.6 (COOH). HRMS 
(found/calculated): 506.1953/506.1849 [M+H]+. IR (film, CHCl3, 
cm−1): 3067, 2957, 2895, 1697, 1522, 1508, 1474, 1451, 1419, 
1356, 1339, 1267, 1140. Synthesis of cis-L-configuration of 4 
was also performed in a similar manner to that described above. 
Yield: 64%. 1H-NMR (300MHz, CDCl3):δ1.9 (m, 3H, thymine 
CH3), 2.1-2.7 (m, 2H, C3′H2), 2.9-4.8 (m, 6H, Cα-CH2-O-CH2-
CO, Fmoc CH, and C2′H), 4.2 (m, 2H, Fmoc CH2), 5.0-5.3 (m, 
2H, C5′H2), 5.6 (m, 1H, C4′H), 7.2-7.8 (m, 9H, Fmoc aromatic 
ring and C6H). 13C-NMR (75 MHz, CDCl3):δ 12.3 (thymine 
CH3), 34.2 (C3′), 47.2 (Fmoc CH), 49.6 (C5′), 51.5 (C4′), 55.7 
(C2′), 66.7 (Fmoc CH2), 67.9 (O-CH2-CO), 71.8 (Cα-CH2-O), 
111.4 (C5), 119.9, 125.0, 127.1, 127.7, 141.2, and 143.8 (Fmoc 
aromatic ring), 137.2 (C6), 151.2 (C2), 154.2 (Fmoc amide), 
164.2 (C4), 172.5 (COOH). HRMS (found/calculated): 
506.1914/506.1849 [M + H]+. IR (film, CHCl3, cm−1): 3066, 
2959, 2930, 2901, 1697, 1522, 1508, 1474, 1452, 1424, 1339, 
1273, 1138. Synthesis of trans-D-configuration of 4 and cis-D-
configuration of 4 were performed according to aforementioned 
protocols and these spectroscopic data were identical with 4 and 
cis-L-configuration of 4, respectively. Trans-D-configuration of 
4; Yield: 36%. HRMS (found/calculated): 506.1931/506.1849 
[M+H]+. Cis-D-configuration of 4; Yield: 40%. HRMS 
(found/calculated): 506.1946/506.1849 [M + H]+. 
4.3. Synthesis of POPNA A monomers 
4.3.1. (2S,4S)-2-tert-Butoxycarbonylmethoxymethyl-4-methane-
sulfonyloxy-pyrrolidine-1-carboxylic acid tert-butyl ester (5)  
Ms-Cl (2.5 g, 21.6 mmol) and TEA (2.2 g, 21.6 mmol) were 
added to a solution of 2 (5.5 g, 16.6 mmol) in dichloromethane 
(DCM, 17 mL) under ice cooling, and the mixture was stirred for 
3 h at room temperature. The mixture was evaporated to dryness. 
The residue was dissolved in water (50 mL) and extracted three 
times with AcOEt (each 50 mL). The AcOEt layer was washed 
with water (50 mL) and brine (50 mL), then, dried over MgSO4. 
Filtration followed by solvent evaporation gave crude viscous oil. 
The crude oil was chromatographed on silica gel with 30/70 
AcOEt/Hex mixture as eluting solvent. The title compound 5 was 
obtained as a colorless viscous oil. Yield: 93%. 1H-NMR 
(300MHz, CDCl3):δ1.5 (s+s, 18H, Boc CH3 and tert-butyl CH3), 
2.2-2.6 (m, 2H, C3′H2), 3.1 (s, 3H, mesyl CH3), 3.4-4.2 (m, 7H, 
C2′H, C5′H2 and Cα-CH2-O-CH2-CO), 5.2 (m, 1H, C4′H). 13C-
NMR (75 MHz, CDCl3):δ 28.1 and 28.4 (Boc CH3 and tert-butyl 
CH3), 34.8 (C3′), 38.7 (mesyl CH3), 53.1 (C5′), 55.5 (C2′), 68.8 
(O-CH2-CO), 71.4 (Cα-CH2-O), 79.1 (C4′), 80.3 and 81.5 (Boc C 
and tert-butyl C), 154.0 (Boc amide), 169.5 (tert-butyl ester). 
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4.3.2(2S,4R)-4-(6-Benzoylamino-purin-9-yl)-2-tert-butoxycarbo-
nylmethoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
(6) 
5 (2.5 g, 6.1 mmol), N6-benzoyladeninne (2.9 g, 12 mmol), 18-
crown-6-ether (1.0 g, 3.8 mmol), and K2CO3 (1.6 g, 12 mmol) 
were added to N, N′-dimethylformamide (DMF, 10 mL). The 
mixture was stirred at 60˚C overnight. The mixture was 
evaporated to dryness. The residue was dissolved in water (50 
mL) and extracted three times with AcOEt (each 50 mL). The 
AcOEt layer was washed with water (50 mL) and brine (50 mL), 
then, dried over MgSO4. Filtration followed by solvent 
evaporation gave crude yellow powder. The crude compound was 
chromatographed on silica gel with 90/10 AcOEt/Hex mixture as 
eluting solvent. The title compound 6 was obtained as a white 
powder. Yield: 41%. Rf (AcOEt/Hex = 7/3 (v/v)): 0.13. 1H-NMR 
(300MHz, CDCl3):δ1.44 and 1.48 (s+s, 18H, Boc CH3 and tert-
butyl CH3), 2.6-2.8 (m, 2H, C3′H2), 3.6-4.4 (m, 7H, C2′H, C5′H2 
and Cα-CH2-O-CH2-CO), 5.42 (m, 1H, C4′H), 7.4-8.0 (m, 5H, 
phenyl), 8.2 (m, 1H, benzoyl amide), 8.77 (s, 1H, C2H), 9.23 (s, 
1H, C8H). 13C-NMR (75 MHz, CDCl3):δ 28.1 and 28.4 (Boc CH3 
and tert-butyl CH3), 33.6 (C3′), 51 (C5′), 53.7 (C4′), 55.9 (C2′), 
69.0 (O-CH2-CO), 71.9 (Cα-CH2-O), 80.3 and 81.7 (Boc C and 
tert-butyl C), 123 (C5), 127.8, 128.8, 132.7, and 133.6 (phenyl), 
129 (C6), 141.3 (C8), 149.5 (C2), 152.4 (C4), 153.9 (Boc amide), 
164.7 (benzoyl amide), 169.4 (tert-butyl ester). 
4.3.3(2S,4R)-4-(6-Benzoylamino-purin-9-yl)-2-carboxymethoxy-
methyl-pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
(7, trans-L-POPNA A monomer) 
6 (1.4 g, 2.5 mmol) was treated with 30% HBr/AcOH (10 mL) 
for 30 min at room temperature. The resultant mixture was 
evaporated to dryness. The residue was dissolved in 5% aqueous 
NaHCO3 (50 mL) to adjust the pH to 8. A solution of Fmoc-OSu 
(0.94 g, 2.8 mmol) in MeCN (50 mL) was added to the aqueous 
solution with stirring under ice cooling. The reaction mixture was 
stirred at room temperature overnight and evaporated to dryness. 
The residue was dissolved in water and the aqueous layer was 
washed three times with Et2O (each 30 mL), acidified to pH 7 
with 5% aqueous KHSO4, and the resultant precipitate was 
collected by filtration. The residue was washed several times 
with water and dried in vacuo. 7 was obtained as a white powder. 
7 was purified by preparatory RP-HPLC (C18 column) before 
using to SPPS. Yield: 77%.1H-NMR (300MHz, CDCl3):δ2.4-3.2 
(m, 3H, C3′H2 and C2′H), 3.5-4.8 (m, 9H, Fmoc CH, C5′H2, Cα-
CH2-O-CH2-CO and Fmoc CH2), 5.48 and 5.67 (m+m, 1H, C4′H, 
rotamer), 7.2-8.2 (m, 13H, Fmoc aromatic ring and phenyl), 8.19 
and 8.29 (s+s, 1H, C8H, rotamer), 8.72 and 8.80 (s+s, 1H, C2H, 
rotamer), 10.52 (br, 1H, COOH). 13C-NMR (75 MHz, CDCl3):δ 
33.6 (C3′), 47.2 (Fmoc CH), 50.5 (C5′), 54.2 (C4′), 56.0 and 56.6 
(C2′), 67.4 (Fmoc CH2), 68.0 (O-CH2-CO), 71.8 (Cα-CH2-O), 
119.9, 124.9, 127.0, 127.7, 141.2, and 143.7 (Fmoc aromatic 
ring), 127.2, 128.4, 132.8, and 133.0 (phenyl), 128.6 (C5), 142.4 
(C8), 149.6 (C4), 151.5 (C6), 152.2 (C2), 154.2 (Fmoc amide), 
165.4 (benzoyl amide), 173.5 (COOH). HRMS 
(found/calculated): 619.2282/619.2227 [M + H]+. IR (film, 
CHCl3, cm−1): 3069, 2895, 1701, 1611, 1518, 1456, 1420, 1339, 
1242, 1138. Synthesis of cis-L-configuration of 7 was also 
performed in an identical manner to that described above. Yield: 
89%. 1H-NMR (300MHz, CDCl3):δ2.3-3.2 (m, 3H, C3′H2 and 
C2′H), 3.2-5.4 (m, 10H, Fmoc CH, C5′H2, Cα-CH2-O-CH2-CO, 
Fmoc CH2 and C4′H), 7.2-7.8 (m, 13H, Fmoc aromatic ring and 
phenyl), 7.96 (br, 1H, C8H), 8.76 and 8.86 (br+br, 1H, C2H, 
rotamer), 10.85 (br, 1H, COOH). 13C-NMR (75 MHz, CDCl3):δ 
32.9 (C3′), 47.2 (Fmoc CH), 51.5 (C5′), 52 (C4′), 55.8 (C2′), 67.2 
(Fmoc CH2), 67.9 (O-CH2-CO), 71.6 (Cα-CH2-O), 119.9, 124.7, 
127.1, 127.7, 141.3, and 143.8 (Fmoc aromatic ring), 128.5 (C5), 
127.4, 128.2, 132.7, and 133.1 (phenyl), 142.5 (C8), 149.2 (C4), 
151 (C6), 151.9 (C2), 154.2 (Fmoc amide), 165.5 (benzoyl 
amide), 172.9 (COOH). HRMS (found/calculated): 
619.2332/619.2227 [M+H]+. IR (film, CHCl3, cm−1): 3069, 2895, 
1699, 1611, 1522, 1452, 1420, 1338, 1246, 1140. Synthesis of 
trans-D-configuration of 7 and cis-D-configuration of 7 were 
performed according to aforementioned protocols and these 
spectroscopic data were identical with 7 and cis-L-configuration 
of 7, respectively. Trans-D-configuration of 7; Yield: 41%. 
HRMS (found/calculated): 619.2332/619.2227 [M + H]+. Cis-D-
configuration of 7; Yield: 9%. HRMS (found/calculated): 
619.2312/619.2227 [M+H]+. 
4.4. Synthesis of POPNA C monomers 
4.4.1. (2S,4R)-4-(4-Benzyloxycarbonylamino-2-oxo-2H-
pyrimidin-1-yl)-2-tert-butoxycarbonylmethoxymethyl-pyrroli-
dine-1-carboxylic acid tert-butyl ester (8) 
5 (2.00 g, 4.88 mmol), N4-Cbz-cytosine (2.99 g, 12.2 mmol), 
18-crown-6 (3.22 g, 12.2 mmol) and K2CO3 (1.68 g, 12.2 mmol) 
were added to DMF (50 mL) and stirred at 65 ˚C overnight. The 
mixture was filtered and evaporated dryness. The crude oil was 
chromatographed on silica gel with 70/30 AcOEt/Hex mixture as 
eluting solvent. The title compound 8 was obtained as a colorless 
viscous oil. Yield: 40%.1H-NMR (300MHz, CDCl3):δ1.44 and 
1.47 (s+s, 18H, Boc CH3 and tert-butyl CH3), 2.35 and 2.55 
(m+m, 2H, C3′H2), 3.4-4.3 (m, 7H, C5′H2, Cα-CH2-O-CH2-CO, 
and C2′H), 5.21 (s, 2H, Cbz CH2), 5.28 (m, 1H, C4′H), 7.1-7.9 
(m, 8H, C6H, phenyl, C5H, and Cbz ester). 13C-NMR (75 MHz, 
CDCl3):δ 28.1 and 28.4 (Boc CH3 and tert-butyl CH3), 32.3 and 
34.2 (C3′), 50 (C5′), 51.1 (C4′), 55.6 (C2′), 67.9 (Cbz CH2), 68.9 
(O-CH2-CO), 71.5 and 72.2 (Cα-CH2-O), 80.2 and 81.6 (Boc C 
and tert-butyl C), 95.2 (C5), 128.3, 128.6, 131, and 134.9 
(phenyl), 145.0 (C6), 152.2 (Cbz ester), 153.9 (Boc amide), 
155.4 (C2), 161.7 (C4), 169.3 (tert-butyl ester). 
4.4.2. (2S,4R)-4-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimi-
din-1-yl)-2-carboxymethoxymethyl-pyrrolidine-1-carboxylic acid 
9H-fluoren-9-ylmethyl ester (9, trans-L-POPNA C monomer) 
8 (0.50 g, 0.89 mmol) was treated with TFA(10mL) for 30 
min at room temperature. The resultant mixture was evaporated 
to dryness. The residue was dissolved in 5% aqueous NaHCO3 
(50 mL) to adjust the pH to 8. A solution of Fmoc-OSu (0.33 g, 
0.98 mmol) in MeCN (50 mL) was added to the aqueous solution 
with stirring under ice cooling. The reaction mixture was stirred 
at room temperature overnight and evaporated to dryness. The 
residue was dissolved in water and the aqueous layer was washed 
three times with Et2O (each 30 mL), acidified to pH 3 with 5% 
aqueous KHSO4, and extracted three times with AcOEt (each 50 
mL). The AcOEt layer was washed with water (50 mL) and brine 
(50 mL) and dried over MgSO4. Filtration followed by solvent 
evaporation gave the title compound 9. 9 was obtained as a white 
powder. 9 was purified by preparatory RP-HPLC (C18 column) 
before using to SPPS. Yield: 54%. 1H-NMR (300MHz, 
CDCl3):δ2.1-3.2 (m, 3H, C3′H2 and C2′H), 3.4-4.8 (m, 9H, Fmoc 
CH, C5′H2, Cα-CH2-O-CH2-CO, and Fmoc CH2), 5.22 (s, 2H, 
Cbz CH2), 5.30 (m, 1H, C4′H), 7.2-7.8 (m, 15H, C6H, Fmoc 
aromatic ring, phenyl, and C5H) , 9.25 (br, 1H, COOH). 13C-
NMR (75 MHz, CDCl3):δ 32.3 and 33.4 (C3′), 47.2 (Fmoc CH), 
50.2 (C5′), 56.2 (C4′), 57.1 (C2′), 66.4 (Cbz CH2), 67.2 (Fmoc 
CH2), 67.8 (O-CH2-CO), 71.4 (Cα-CH2-O), 96.0 (C5), 119.9, 
124.8, 127.1, 127.7, 141.2, and 143.7 (Fmoc aromatic ring), 
124.4, 128.1, 128.5, and 135.0 (phenyl), 145.5 (C6), 152.8 (Cbz 
ester), 154.3 (Fmoc amide), 154.9 (C2), 162.2 (C4), 172.8 
(COOH). HRMS (found/calculated): 625.2314/625.2220 [M+H]+. 
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Synthesis of cis-L-configuration of 9 was also performed in an 
identical manner to that described above. Yield: 10% at 2 steps. 
1H-NMR (300MHz, CDCl3):δ1.9-3.2 (m, 4H, C3′H2 and C5′H2), 
3.4-4.8 (m, 8H, Cα-CH2-O-CH2-CO, Fmoc CH, Fmoc CH2 and 
C2′H), 5.2-5.5 (m, 3H, C4′H and Cbz CH2), 7.1-8.8 (m, 15H, 
C6H, Fmoc aromatic ring, phenyl, and C5H). 13C-NMR (75 MHz, 
CDCl3):δ 33.2 (C3′), 47.4 (Fmoc CH), 51.5 (C5′), 52 (C4′), 55.8 
(C2′), 67.1 (Cbz CH2), 68.0 (Fmoc CH2), 68.4 (O-CH2-CO), 72.8 
(Cα-CH2-O), 96.3 (C5), 120.0, 124.8, 126.9, 127.1, 141.3, and 
143.8 (Fmoc aromatic ring), 124, 127.8, 128.3, and 134.8 
(phenyl), 148.6 (C6), 153.0 (Cbz ester), 154.0 (Fmoc amide), 154 
(C2), 162.0 (C4), 175.9 (COOH). HRMS (found/calculated): 
625.2305/625.2220 [M + H]+. IR (film, CHCl3, cm−1): 1751, 
1697, 1624, 1558, 1508, 1452, 1429, 1400, 1354, 1253, 1140, 
1124, 1071, 1005. Synthesis of trans-D-configuration of 9 and 
cis-D-configuration of 9 were performed according to 
aforementioned protocols and these spectroscopic data were 
identical with 9 and cis-L-configuration of 9, respectively. Trans-
D-configuration of 9; Yield: 5% at 2 steps. HRMS 
(found/calculated): 625.2323/625.2220 [M + H]+. Cis-D-
configuration of 9; Yield: 33% HRMS (found/calculated): 
625.2326/625.2220 [M + H]+. IR (film, CHCl3, cm−1): 1748, 
1701, 1654, 1628, 1558, 1521, 1450, 1420, 1352, 1331, 1142, 
1103, 1069, 993, 974. 
4.5. Synthesis of POPNA G monomers 
4.5.1. (2S,4R)-4-(2-Amino-6-chloro-purin-9-yl)-2-tert-butoxycar-
bonylmethoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl 
ester (10) 
5 (5.0 g, 12.4 mmol), 2-amino-6-chloropurin (6.3 g, 37.1 mmol), 
18-crown-6-ether (9.8 g, 37.1 mmol), and K2CO3 (5.1 g, 37.1 
mmol) were added to DMF (50 mL) and stirred at 65 ˚C 
overnight. The mixture was filtered and evaporated to dryness. 
The mixture was added to AcOEt and the insoluble residue was 
removed. The crude oil was chromatographed on silica gel with 
70/30AcOEt/Hex mixture as the eluting solvent. The title 
compound 10 was obtained as a colorless viscous oil. Yield: 36%. 
1H-NMR (300 MHz, CDCl3):δ1.45 and 1.46 (s+s, 18H, Boc CH3 
and tert-butyl CH3), 2.61 (t, 2H, C3′H2), 3.5-4.3 (m, 7H, C2′H, 
C5′H2 and Cα-CH2-O-CH2-CO), 5.17 (m, 1H, C4′H), 5.29 (br, 2H, 
NH2), 7.75 (s, 1H, C8H). 13C-NMR (75 MHz, CDCl3):δ 28.1 and 
28.4 (Boc CH3 and tert-butyl CH3), 33.4 and 34.6 (C3′), 50.5 and 
51.2 (C5′), 52.8 and 53.5 (C4′), 55.9 (C2′), 68.9 (O-CH2-CO), 
71.9 (Cα-CH2-O), 80.3 and 81.7 (Boc C and tert-butyl C), 125.5 
(C5), 140.5 (C8), 151.4 (C2), 153.5 (Boc amide), 158.9 (C4), 
162.5 (C6), 169.3 (tert-butyl ester). 
4.5.2. (2S,4R)-4-[2-Amino-6-(2-nitro-phenoxy)-purin-9-yl]-2-
tert-butoxycarbonylmethoxymethyl-pyrrolidine-1-carboxylic acid 
tert-butyl ester (11). DABCO (0.46 g, 4.15 mmol) and TEA (1.26 
g, 12.45 mmol) were added to a solution of 10 (2.00 g, 4.15 
mmol) in 1,2-dichloroethane (20 mL) and the mixture was stirred 
at room temperature overnight. The mixture was evaporated to 
dryness. The residue was dissolved in water (100 mL) and 
extracted three times with DCM (each 50 mL). The DCM layer 
was washed with water (100 mL) and brine (100 mL), and it was 
then dried over MgSO4. Filtration followed by solvent 
evaporation gave crude viscous oil. The crude oil was 
chromatographed on silica gel with 70/30AcOEt/Hex mixture as 
the eluting solvent. The title compound 11 was obtained as a 
yellow crystal. Yield: 78%. 1H-NMR (300 MHz, CDCl3):δ1.45 
and 1.47 (s+s, 18H, Boc CH3 and tert-butyl CH3), 2.62 (m, 2H, 
C3′H2), 3.5-4.4 (m, 7H, C2′H, C5′H2 and Cα-CH2-O-CH2-CO), 
4.84 (br, 2H, NH2), 5.16 (m, 1H, C4′H), 7.41, 7.67, and 8.09 
(t+t+d, 4H, phenyl), 7.69 (s, 1H, C8H). 13C-NMR (75 MHz, 
CDCl3):δ 28.1 and 28.4 (Boc CH3 and tert-butyl CH3), 33.4 and 
34.7 (C3′), 51.3 (C5′), 52.6 and 53.2 (C4′), 55.9 (C2′), 69.0 (O-
CH2-CO), 71.9 (Cα-CH2-O), 80.2 and 81.6 (Boc C and tert-butyl 
C), 115.6 (C5), 125.3, 125.5, 126.0, 134.5, 142.5, and 145.5 
(phenyl), 138.9 (C8), 155.2 and 158.5 (C2 and C6), 154.1 (Boc 
amide), 159.1 (C4), 169.4 (tert-butyl ester). 
4.5.3. (2S,4R)-2-tert-Butoxycarbonylmethoxymethyl-4-[2-isobu-
tyrylamino-6-(2-nitro-phenoxy)-purin-9-yl]-pyrrolidine-1-carbo-
xylic acid tert-butyl ester (12).11 (1.9 g, 3.2 mmol) was dissolved 
in pyridine and iPrCOCl (0.42 g, 3.9 mmol) was added to the 
solution of 11 in pyridine (20 mL) under ice cooling and the 
mixture was stirred at room temperature overnight. The mixture 
was then evaporated to dryness. The residue was added to water 
(100 mL) and extracted three times with AcOEt (each 100 mL). 
The AcOEt layer was washed with 5% aqueous citric acid (100 
mL) and water (100 mL), and it was then dried over MgSO4. 
Filtration followed by solvent evaporation gave crude viscous oil. 
The crude oil was chromatographed on silica gel with 
70/30AcOEt/Hex mixture as the eluting solvent. The title 
compound 12 was obtained as yellow foam. Yield: quant. 1H-
NMR (300 MHz, CDCl3):δ1.03 and 1.05 (d, 6H, iso-butyl CH3), 
1.46 and 1.48 (s+s, 18H, Boc CH3 and tert-butyl CH3), 2.6-2.8 
(m, 2H, C3′H2), 3.16 (m, 1H, iso-butyl CH), 3.6-4.3 (m, 7H, 
C2′H, C5′H2 and Cα-CH2-O-CH2-CO), 5.32 (m, 1H, C4′H), 7.4-
8.2 (m+m+d, 5H, phenyl and C8H), 7.92 (s, 1H, iso-butyl amide). 
13C-NMR (75 MHz, CDCl3):δ 18.8 (iso-butyl CH3), 28.1 and 
28.4 (Boc CH3 and tert-butyl CH3), 33.5 (C3′), 34.2 (iso-butyl 
CH), 51.3 (C5′), 53.8 (C4′), 55.9 (C2′), 68.9 (O-CH2-CO), 71.9 
and 72.5 (Cα-CH2-O), 80.3 and 81.7 (Boc C and tert-butyl C), 
118.0 (C5), 125.5, 125.8, 126.6, 134.8, 142.2, and 145.5 (phenyl), 
141.3 (C8), 151.2 (C2), 154.2 (C6), 154 (Boc amide), 159.3 (C4), 
169.3 (tert-butyl ester), 177.3 (iso-butyl amide). 
4.5.4. (2S,4R)-2-tert-Butoxycarbonylmethoxymethyl-4-(2-isobuty-
rylamino-6-oxo-1,6-dihydro-purin-9-yl)-pyrrolidine-1-carboxylic 
acid tert-butyl ester (13). 12 (2.2 g, 3.3 mmol) and 2-
nitrobenzaldoxime (5.5 g, 33 mmol) were dissolved in MeCN (30 
mL), and 1,1,3,3-tetramethylguanidine (3.5 g, 30 mmol) was 
added to the solution. The mixture was stirred at room 
temperature overnight. The mixture was evaporated to dryness. 
The residue was dissolved in water (100 mL) and extracted five 
times with DCM (each 100 mL). The DCM layer was washed 
with water (100 mL) and brine (100 mL), and it was then dried 
over MgSO4. Filtration followed by solvent evaporation gave a 
crude viscous oil. The crude oil was chromatographed on silica 
gel with 95/5AcOEt/MeOH mixture as the eluting solvent. The 
title compound 13 was obtained as a white powder. Yield: 50%. 
1H-NMR (300 MHz, CDCl3):δ1.22 and 1.24 (d, 6H, iso-butyl 
CH3), 1.42 and 1.45 (s+s, 18H, Boc CH3 and tert-butyl CH3), 2.4-
2.8 (m, 3H, C3′H2 and iso-butyl CH), 3.5-4.3 (m, 7H, C2′H, 
C5′H2 and Cα-CH2-O-CH2-CO), 5.02 (m, 1H, C4′H), 7.61 (s, 1H, 
C8H), 9.37 (br, 1H, iso-butyl amide), 12.08 (br, 1H, C1H). 13C-
NMR (75 MHz, CDCl3):δ 18.9 and 19.0 (iso-butyl CH3), 28.1 
and 28.4 (Boc CH3 and tert-butyl CH3), 34.0 (C3′), 36.3 (iso-
butyl CH), 50.9 (C5′), 52.1 (C4′), 56.0 (C2′), 68.9 (O-CH2-CO), 
71.9 (Cα-CH2-O), 80.3 and 81.8 (Boc C and tert-butyl C), 121.6 
(C5), 137.2 (C8), 147.3 and 148.1 (C2 and C6), 154.3 (Boc 
amide), 155.7 (C4), 169.6 (tert-butyl ester), 178.8 (iso-butyl 
amide). 
4.5.5. (2S,4R)-2-Carboxymethoxymethyl-4-(2-isobutyrylamino-6-
oxo-1,6-dihydro-purin-9-yl)-pyrrolidine-1-carboxylic acid 9H-
fluoren-9-ylmethyl ester (14, trans-L-POPNA G monomer). 13 
(0.9 g, 1.6 mmol) was treated with 30% HBr/AcOH (10 mL) for 
30 min at room temperature. The resultant mixture was 
evaporated to dryness. The residue was dissolved in 5% aqueous 
NaHCO3 to adjust the pH to 8 (30 mL). A solution of Fmoc-OSu 
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(0.6 g, 1.8 mmol) in MeCN (30 mL) was added to the aqueous 
solution with stirring under ice cooling. The reaction mixture was 
stirred at room temperature overnight and evaporated to dryness. 
The residue was dissolved in water and the aqueous layer was 
washed three times with Et2O (each 30 mL) and acidified to pH 7 
with 5% aqueous KHSO4; the resultant precipitate was collected 
by filtration. The residue was washed several times with water 
and dried in vacuo. 14 was obtained as a white powder. 14 was 
purified by preparatory RP-HPLC (C18 column) before using 
SPPS. Yield: 40%. 1H-NMR (300 MHz, CDCl3):δ1.20 and 1.22 
(d, 6H, iso-butyl CH3), 2.2-2.8 (m, 3H, iso-butyl CH and C3′H2), 
3.1 (m, 1H, C2′H), 3.3-4.7 (m, 9H, Fmoc CH, C5′H2, Cα-CH2-O-
CH2-CO, and Fmoc CH2), 5.0-5.3 (m, 1H, C4′H), 7.1-7.9 (m, 9H, 
Fmoc aromatic ring and C8H), 8.67 (d, 1H, iso-butyl amide), 
10.0-10.3 (br, 1H, COOH), 12.32 (br, 1H, C1H). 13C-NMR (75 
MHz, CDCl3):δ 19.0 (iso-butyl CH3), 33.7 (C3′), 36.1 (iso-butyl 
CH), 47.0 (Fmoc CH), 51.0 (C5′), 52.7 (C4′), 56.7 (C2′), 67.4 
(Fmoc CH2), 68 (O-CH2-CO), 71.6 (Cα-CH2-O), 119.9, 124.8, 
126.9, 127.7, 141.1, and 143.6 (Fmoc aromatic ring), 124 (C5), 
138.4 (C8), 147.9 and 148.4 (C2 and C6), 154.3 and 154.7 (Fmoc 
amide), 155.5 (C4), 172.7 (COOH), 179.7 (iso-butyl amide). 
HRMS (found/calculated): 601.2391/601.2332 [M+H]+. 
Synthesis of cis-L-configuration of 14 was also performed in a 
manner identical to that described above. Yield: 96%. Rf 
(AcOEt/MeOH = 9/1 (v/v)): 0.38. 1H-NMR (300 MHz, 
CDCl3):δ1.19 and 1.21 (d, 6H, iso-butyl CH3), 2.3-3.0 (m, 3H, 
iso-butyl CH and C3′H2), 3.1 (m, 1H, C2′H), 3.4-4.9 (m, 10H, 
Fmoc CH, C5′H2, Cα-CH2-O-CH2-CO, Fmoc CH2 and C4′H), 
7.2-8.0 (m, 9H, Fmoc aromatic ring and C8H), 8.50 (d, 1H, iso-
butyl amide), 9.6-9.9 (br, 1H, COOH), 12.19 (br, 1H, C1H). 13C-
NMR (75 MHz, CDCl3):δ 18.9 (iso-butyl CH3), 32.5 (C3′), 36.0 
(iso-butyl CH), 47.1 (Fmoc CH), 50.6 (C5′), 52.4 (C4′), 56.2 
(C2′), 66.6 (Fmoc CH2), 68.0 (O-CH2-CO), 70.8 (Cα-CH2-O), 
119.9, 124.9, 127.1, 127.7, 141.2, and 143.7 (Fmoc aromatic 
ring), 124.5 (C5), 138.5 (C8), 147.7 and 148.6 (C2 and C6), 
154.2 (Fmoc amide), 155.4 (C4), 172.4 (COOH), 179.6 (iso-
butyl amide). HRMS (found/calculated): 601.2437/601.2332 [M 
+ H]+. IR (film, CHCl3, cm−1): 3066, 2901, 1732, 1684, 1608, 
1559, 1474, 1452, 1418, 1356, 1250, 1140, 1103, 1069, 993, 974. 
Synthesis of the trans-D-configuration of 14 and cis-D-
configuration of 14 were performed according to aforementioned 
protocols, and the spectroscopic data were identical with those of 
14 and the cis-L-configuration of 14, respectively. Trans-D-
configuration of 14; Yield: 36%. HRMS (found/calculated): 
601.2403/601.2332 [M + H]+. Cis-D-configuration of 14; Yield: 
50%. HRMS (found/calculated): 601.2432/601.2332 [M + H]+. 
IR (film, CHCl3, cm−1): 3066, 2901, 1683, 1607, 1559, 1474, 
1451, 1418, 1362, 1317, 1250, 1190, 1142, 1031, 930. 
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